First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
SSRN Electronic Journal（2023）
摘要
F Hoffmann-La Roche and Genentech Inc, a member of the Roche group.
更多查看译文
关键词
chemotherapy,lung cancer,first-line,single-agent,non-small-cell,platinum-containing,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要